Furthermore, astrocyte-derived BDNF has been identified as mediator of the therapeutic functions of glatiramer acetate (GA), a FDA-approved drug for the treatment of relapse-remitting MS (RRMS) in a mouse model of neurodegeneration, demonstrating the potential of astrocyte-derived BDNF for future therapeutic strategies (128). This evidence concerns the gene BDNF and relapsing-remitting multiple sclerosis.